These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 37124230)

  • 1. Fighting cytokine storm and immunomodulatory deficiency: By using natural products therapy up to now.
    Mohammed MA
    Front Pharmacol; 2023; 14():1111329. PubMed ID: 37124230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phytotherapy for treatment of cytokine storm in COVID-19.
    Sapra L; Bhardwaj A; Azam Z; Madhry D; Verma B; Rathore S; Srivastava RK
    Front Biosci (Landmark Ed); 2021 Apr; 26(5):51-75. PubMed ID: 34027650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy.
    Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Ronconi G
    J Biol Regul Homeost Agents; 2020; 34(6):1971-1975. PubMed ID: 33016027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Coronavirus Disease 2019 (COVID-19) and Cytokine Storms for More Effective Treatments from an Inflammatory Pathophysiology.
    Yokota S; Miyamae T; Kuroiwa Y; Nishioka K
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33671159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can
    Choi JH; Lee YH; Kwon TW; Ko SG; Nah SY; Cho IH
    J Ginseng Res; 2022 May; 46(3):337-347. PubMed ID: 35233163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
    Atluri S; Manchikanti L; Hirsch JA
    Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmaco-Immunomodulatory Therapy in COVID-19.
    Rizk JG; Kalantar-Zadeh K; Mehra MR; Lavie CJ; Rizk Y; Forthal DN
    Drugs; 2020 Sep; 80(13):1267-1292. PubMed ID: 32696108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets.
    Misra DP; Agarwal V; Gasparyan AY; Zimba O
    Clin Rheumatol; 2020 Jul; 39(7):2055-2062. PubMed ID: 32277367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
    Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
    Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy.
    Drożdżal S; Rosik J; Lechowicz K; Machaj F; Kotfis K; Ghavami S; Łos MJ
    Drug Resist Updat; 2020 Dec; 53():100719. PubMed ID: 32717568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine and dexamethasone in COVID-19: who won and who lost?
    Ortolani C; Pastorello EA
    Clin Mol Allergy; 2020; 18():17. PubMed ID: 32922210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Present and future treatment strategies for coronavirus disease 2019.
    Elekhnawy E; Kamar AA; Sonbol F
    Futur J Pharm Sci; 2021; 7(1):84. PubMed ID: 33850936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials.
    Siordia JA; Bernaba M; Yoshino K; Ulhaque A; Kumar S; Bernaba M; Bergin E
    SN Compr Clin Med; 2020; 2(8):1120-1131. PubMed ID: 32838169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can mesenchymal stem cell therapy be the interim management of COVID-19?
    Bamba C; Singh SP; Choudhury S
    Drug Discov Ther; 2020 Jul; 14(3):139-142. PubMed ID: 32554953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm.
    Rabiu Abubakar A; Ahmad R; Rowaiye AB; Rahman S; Iskandar K; Dutta S; Oli AN; Dhingra S; Tor MA; Etando A; Kumar S; Irfan M; Gowere M; Chowdhury K; Akter F; Jahan D; Schellack N; Haque M
    Life (Basel); 2022 Mar; 12(4):. PubMed ID: 35454970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging pharmacotherapies for COVID-19.
    Salvi R; Patankar P
    Biomed Pharmacother; 2020 Aug; 128():110267. PubMed ID: 32410772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.